

Media Release

Straumann is granted a controlling interest in Medentika

- *Highly successful partnership continues with fast-growing provider of attractively-priced prosthetics for most leading implant systems*
- *Straumann to consolidate Medentika fully in its 2017 financial statements*

Basel, 30 November 2016: Straumann has signed an agreement with the other shareholders of Medentika to obtain a controlling interest in Medentika. At the same time Straumann is acquiring Medentika's share of their jointly-held distribution business in Germany, Medentika's biggest market.

The two companies became partners three years ago, when Straumann purchased a 51% non-controlling stake in Medentika. The original agreement foresaw Straumann gaining a controlling interest in November 2017 but the two companies have agreed to bring this forward in order to deepen their relationship and to add organizational clarity to their common activities.

With effect of 1 January 2017, Straumann will therefore fully consolidate Medentika's financial statements and balance sheet. The ownership structure of Medentika – and Straumann's stake – remain unchanged and the founding shareholders will continue to have an active role in the company.

The partnership between the two companies has been highly successful: through its Intradent platform, Straumann has assisted Medentika's international expansion and has made a significant contribution to the company's development and sustainable growth. For its part, Medentika has contributed significantly to Straumann's strategic goals of providing comprehensive solutions to dental labs and becoming a global leader in the 'value' segment of the tooth-replacement market.

About Medentika

Founded in 2005 and based in Hügelsheim, Germany, Medentika is a fast-growing provider of attractively-priced implant prosthetics for most leading implant and CAD/CAM systems. The company also supplies a range of titanium implants and instruments and is certified to EN ISO 13485:2007 and AC:2009.

With a staff of approximately 70, Medentika is highly profitable and generated revenues of approximately CHF 20 million in 2015. Straumann will also recognize a financial liability of approximately CHF 46 million in connection with the accounting treatment of the outstanding minority stake. Apart from this, no other significant impacts are to be expected.

About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and biomaterials for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately

3600 people worldwide and its products and services are available in more than 100 countries through its broad network of distribution subsidiaries and partners. To complement its core premium business, Straumann has established the Intradent business platform to address the global non-premium segment with various brands that it either owns or in which it has invested including Anthogyr, equinox, Medentika and Neodent.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.
Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01
Homepage: www.straumann.com

Contacts:

Corporate Communication

Mark Hill: +41 (0)61 965 13 21
Thomas Konrad: +41 (0)61 965 15 46
E-mail: corporate.communication@straumann.com

Investor Relations

Fabian Hildbrand: +41 (0)61 965 13 27
E-mail: investor.relations@straumann.com

Disclaimer

This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Straumann Media Releases subscription:

www.straumann.com/en/home/investor-relations/ir-contacts-and-services/subscription.html

RSS feed subscription:

www.straumann.com/en/home/media/media-releases.news.rss

Straumann Social Media Channels

<http://www.straumann.com/en/home/about-straumann/social-media.html>

Straumann Media Center (login: "Corporate"; password: "corporate")

smc.straumann.com

#